{"transactions":[{"id":4636033,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit (RSU)","published_at":"2026-10-06T20:15:13.000Z","date":"2026-10-05","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/4 of the total award on each of October 5, 2027, October 5, 2028, October 5, 2029 and October 5, 2030 subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":200000,"derivative":{"expiration_date":"2030-10-05","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001953943-26-000004","document":"form4-10062026_081008.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1953943/000195394326000004/form4-10062026_081008.xml","form_type":"4"}},{"id":4636032,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-06T20:15:13.000Z","date":"2026-10-05","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 1/4 of the total award on the first anniversary of October 5, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":7.01,"expiration_date":"2036-10-05","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001953943-26-000004","document":"form4-10062026_081008.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1953943/000195394326000004/form4-10062026_081008.xml","form_type":"4"}},{"id":710564,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-13T20:03:43.000Z","date":"2026-07-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":221270,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation (\"Parent\") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"MergerCo\"), pursuant to which, on July 13, 2026 (the \"Effective Time\"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."}],"balance_after":0,"derivative":{"exercise_price":2.44,"expiration_date":"2036-03-13","underlying":"Common Stock","underlying_shares":221270},"source":{"system":"sec-edgar","filing":"0001628280-26-048000","document":"wk-form4_1783973020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026048000/wk-form4_1783973020.xml","form_type":"4"}},{"id":710563,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-13T20:03:43.000Z","date":"2026-07-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":213000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation (\"Parent\") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"MergerCo\"), pursuant to which, on July 13, 2026 (the \"Effective Time\"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."}],"balance_after":0,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-14","underlying":"Common Stock","underlying_shares":213000},"source":{"system":"sec-edgar","filing":"0001628280-26-048000","document":"wk-form4_1783973020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026048000/wk-form4_1783973020.xml","form_type":"4"}},{"id":710562,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-13T20:03:43.000Z","date":"2026-07-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation (\"Parent\") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"MergerCo\"), pursuant to which, on July 13, 2026 (the \"Effective Time\"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."}],"balance_after":0,"derivative":{"exercise_price":2.05,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001628280-26-048000","document":"wk-form4_1783973020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026048000/wk-form4_1783973020.xml","form_type":"4"}},{"id":710561,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-13T20:03:43.000Z","date":"2026-07-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":705410,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation (\"Parent\") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"MergerCo\"), pursuant to which, on July 13, 2026 (the \"Effective Time\"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the \"per share cash consideration\"), and (b) one contractual contingent value right per share (each, a \"CVR\" and, together with the per share cash consideration, the \"merger consideration\"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 477,191 restricted stock units (each, a \"RSU\"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions."},{"field":"shares","element":"transactionShares","label":"F4","text":"Includes 2,581 shares recently acquired in Esperion's Employee Stock Purchase Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the \"per share cash consideration\"), and (b) one contractual contingent value right per share (each, a \"CVR\" and, together with the per share cash consideration, the \"merger consideration\"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Includes 477,191 restricted stock units (each, a \"RSU\"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-048000","document":"wk-form4_1783973020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026048000/wk-form4_1783973020.xml","form_type":"4"}},{"id":731917,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-18T20:05:51.000Z","date":"2026-06-17","kind":"sale","planned":false,"acquired":false,"shares":10773,"price":3.155,"value":33988.815,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."}],"balance_after":702829,"source":{"system":"sec-edgar","filing":"0001628280-26-044264","document":"wk-form4_1781813149.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026044264/wk-form4_1781813149.xml","form_type":"4"}},{"id":834819,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:12:52.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":6424,"price":2.705,"value":17376.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."}],"balance_after":713602,"source":{"system":"sec-edgar","filing":"0001628280-26-019409","document":"wk-form4_1773864769.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026019409/wk-form4_1773864769.xml","form_type":"4"}},{"id":841496,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-16T20:19:29.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":221270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026."}],"balance_after":221270,"derivative":{"exercise_price":2.44,"expiration_date":"2036-03-13","underlying":"Common Stock","underlying_shares":221270},"source":{"system":"sec-edgar","filing":"0001628280-26-018186","document":"wk-form4_1773692366.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026018186/wk-form4_1773692366.xml","form_type":"4"}},{"id":841495,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-16T20:19:29.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":247430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,071 shares recently acquired in Esperion's Employee Stock Purchase Plan."}],"balance_after":720026,"source":{"system":"sec-edgar","filing":"0001628280-26-018186","document":"wk-form4_1773692366.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026018186/wk-form4_1773692366.xml","form_type":"4"}},{"id":963073,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:09:36.000Z","date":"2025-12-17","kind":"sale","planned":false,"acquired":false,"shares":7337,"price":3.667,"value":26904.779,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."}],"balance_after":467525,"source":{"system":"sec-edgar","filing":"0001628280-25-057942","document":"wk-form4_1766092168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025057942/wk-form4_1766092168.xml","form_type":"4"}},{"id":1036264,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-18T20:06:08.000Z","date":"2025-09-17","kind":"sale","planned":false,"acquired":false,"shares":7046,"price":2.808,"value":19785.168,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,446 shares recently acquired in Esperion's Employee Stock Purchase Plan."}],"balance_after":474862,"source":{"system":"sec-edgar","filing":"0001953943-25-000004","document":"wk-form4_1758225965.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000195394325000004/wk-form4_1758225965.xml","form_type":"4"}},{"id":1084652,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-18T20:05:21.000Z","date":"2025-07-17","kind":"sale","planned":false,"acquired":false,"shares":11,"price":1.115,"value":12.265,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."}],"balance_after":474462,"source":{"system":"sec-edgar","filing":"0001628280-25-035334","document":"wk-form4_1752869115.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025035334/wk-form4_1752869115.xml","form_type":"4"}},{"id":1106155,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-18T22:44:26.000Z","date":"2025-06-17","kind":"sale","planned":false,"acquired":false,"shares":7229,"price":1.152,"value":8327.808,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."}],"balance_after":474473,"source":{"system":"sec-edgar","filing":"0001628280-25-032217","document":"wk-form4_1750286660.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025032217/wk-form4_1750286660.xml","form_type":"4"}},{"id":1168299,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-04-21T20:03:41.000Z","date":"2025-04-17","kind":"sale","planned":false,"acquired":false,"shares":8,"price":0.964,"value":7.712,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."}],"balance_after":481702,"source":{"system":"sec-edgar","filing":"0001628280-25-018566","document":"wk-form4_1745265814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025018566/wk-form4_1745265814.xml","form_type":"4"}},{"id":1196974,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-19T20:03:18.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":3535,"price":1.483,"value":5242.405,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."}],"balance_after":481710,"source":{"system":"sec-edgar","filing":"0001628280-25-013812","document":"wk-form4_1742414592.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025013812/wk-form4_1742414592.xml","form_type":"4"}},{"id":1203648,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-17T21:16:56.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":213000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be in June 15, 2025."}],"balance_after":213000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-14","underlying":"Common Stock","underlying_shares":213000},"source":{"system":"sec-edgar","filing":"0001628280-25-013198","document":"wk-form4_1742246208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025013198/wk-form4_1742246208.xml","form_type":"4"}},{"id":1203647,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-17T21:16:56.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":238000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be in June 15, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,574 shares recently acquired in Esperion's Employee Stock Purchase Plan."}],"balance_after":485245,"source":{"system":"sec-edgar","filing":"0001628280-25-013198","document":"wk-form4_1742246208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025013198/wk-form4_1742246208.xml","form_type":"4"}},{"id":1255575,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-20T21:50:13.000Z","date":"2025-02-19","kind":"sale","planned":false,"acquired":false,"shares":11,"price":1.86,"value":20.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."}],"balance_after":240671,"source":{"system":"sec-edgar","filing":"0001628280-25-006801","document":"wk-form4_1740088204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025006801/wk-form4_1740088204.xml","form_type":"4"}},{"id":1298710,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-21T21:38:57.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":9,"price":2.265,"value":20.385,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."}],"balance_after":240682,"source":{"system":"sec-edgar","filing":"0001628280-25-002037","document":"wk-form4_1737495531.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025002037/wk-form4_1737495531.xml","form_type":"4"}},{"id":1326518,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-18T21:14:42.000Z","date":"2024-12-17","kind":"sale","planned":false,"acquired":false,"shares":3245,"price":2.424,"value":7865.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."}],"balance_after":240691,"source":{"system":"sec-edgar","filing":"0001628280-24-051875","document":"wk-form4_1734556476.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024051875/wk-form4_1734556476.xml","form_type":"4"}},{"id":1574622,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-15T20:32:14.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2024."}],"balance_after":200000,"derivative":{"exercise_price":2.05,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001628280-24-011488","document":"wk-form4_1710534711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024011488/wk-form4_1710534711.xml","form_type":"4"}},{"id":1574621,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-15T20:32:14.000Z","date":"2024-03-14","kind":"grant","planned":false,"acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2024."}],"balance_after":243936,"source":{"system":"sec-edgar","filing":"0001628280-24-011488","document":"wk-form4_1710534711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024011488/wk-form4_1710534711.xml","form_type":"4"}},{"id":1952076,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-15T13:21:21.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Such options will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service."}],"balance_after":39000,"derivative":{"exercise_price":4.02,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001628280-23-007968","document":"wf-form4_167888646953394.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023007968/wf-form4_167888646953394.xml","form_type":"4"}},{"id":1952075,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-15T13:21:21.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Such award will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of 73,936 shares of common stock held, including 2,306 shares recently acquired in Esperion's Employee Stock Purchase Plan."}],"balance_after":73936,"source":{"system":"sec-edgar","filing":"0001628280-23-007968","document":"wf-form4_167888646953394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023007968/wf-form4_167888646953394.xml","form_type":"4"}},{"id":2089559,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-12T21:07:42.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options will vest over a four (4) year period as follows: 25% shall vest on the one year anniversary of December 15, 2022 and the remainder shall vest in equal quarterly installments over the three (3) year period thereafter, subject to continued service."}],"balance_after":66000,"derivative":{"exercise_price":5.09,"expiration_date":"2032-12-09","underlying":"Common Stock","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001104659-22-126269","document":"tm2232259-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000110465922126269/tm2232259-1_4seq1.xml","form_type":"4"}},{"id":2089558,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30799,"kind":"person","name":"Halladay Benjamin","position":1,"cik":"0001953943","reported_name":"Halladay Benjamin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-12T21:07:42.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Such award will vest over a four (4) year period as follows: 25% shall vest on the one year anniversary of December 15, 2022 and the remainder shall vest in equal quarterly installments over the three (3) year period thereafter, subject to continued service."}],"balance_after":63771,"source":{"system":"sec-edgar","filing":"0001104659-22-126269","document":"tm2232259-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000110465922126269/tm2232259-1_4seq1.xml","form_type":"4"}}]}